GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022 April 11, 2022
GT Biopharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update March 28, 2022
GT Biopharma Presents TriKE® Nanobody Pipeline (GTB-5550) Preclinical Multiple Myeloma Proof-of-Concept Data at 2022 EBMT Annual Meeting March 21, 2022
GT Biopharma Presented Preclinical Data Demonstrating Novel Mesothelin-Targeted TriKE® Driving Cytotoxicity Across All Stages of Non-Small Cell Lung Cancer at ESMO TAT 2022 March 9, 2022
GT Biopharma to Participate In-Person at 34th Annual ROTH Conference, March 13-15, 2022 March 3, 2022
GT Biopharma Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) January 6, 2022
GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021 December 8, 2021
